Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab plus glucocorticoid taper in polymyalgia rheumatica
2022-501895-25-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Secukinumab plus prednisone taper with Placebo plus prednisone taper (2 arms). Primary endpoint: Proportion of participants achieving sustained remission at Week 52. Started Sep 2023; status: completed.
02
Drugs
secukinumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2022-501895-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501895-25-00.